Sector News

Jamere Jackson elected to Lilly Board of Directors

August 31, 2016
Life sciences

The board of directors of Eli Lilly and Company has elected Jamere Jackson as a new member, effective October 1, 2016. As a member of Lilly’s board, he will serve on the Audit and Finance committees.

Jackson is currently chief financial officer of Nielsen Holdings plc (Nielsen).

“I am delighted to welcome Jamere Jackson to the Lilly board,” said John C. Lechleiter, Ph.D., chairman, president and chief executive officer. “Jamere brings a wealth of global financial experience, including a strong background in strategic planning. His experience at Nielsen will also provide an important perspective to our business and help broaden our understanding of consumer markets and strategies.”

Prior to joining Nielsen in 2014, Jackson was with General Electric (GE). His last position there was vice president and chief financial officer for GE Oil & Gas, drilling and surface division. In that role, he was responsible for driving financial rigor, developing strategy and implementing change across the drilling and surface portfolio.

Jackson joined GE in 2004 as the chief financial officer for Global Business Services. He then became chief financial analyst for GE Corporate before being promoted to chief financial officer for GE Aviation Military Systems. Next, he was named chief financial officer for GE Aviation Systems, where he led a global team focused on expanding GE’s jet-engine business beyond its core products.

Jackson’s experience also includes positions at First Data Corporation, Total System Services, Pizza Hut Inc., and Procter & Gamble Company. He is a certified public accountant and received his undergraduate degree in finance and business economics from the University of Notre Dame.

Source: Eli Lilly and Company

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.